Back to Search
Start Over
Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A nationwide, population-based cohort study.
- Source :
-
International journal of rheumatic diseases [Int J Rheum Dis] 2024 Jan; Vol. 27 (1), pp. e15003. Date of Electronic Publication: 2023 Dec 11. - Publication Year :
- 2024
-
Abstract
- Objectives: To assess the association between antirheumatic drugs and of the risk of nonalcoholic fatty liver disease (NAFLD) in a nationwide rheumatoid arthritis (RA) cohort.<br />Methods: Using claim data from the 2000-2020 National Health Insurance Research Database, we identified 21 457 incident patients with RA from 2002 to 2020 without prior liver diseases. A time-varying multivariable Cox regression model was applied to estimate for the association of NAFLD with the use of antirheumatic drugs after adjusting potential confounders, show as adjusted hazard ratios (aHRs) with 95% confidence interval (CIs). Subgroup analyses were conducted based on age-, sex-, and obesity-related comorbidities.<br />Results: Multivariable time-dependent Cox regression analyses showed that defined daily dose (DDD) of NSAID (aHR, 1.03; 95% CI: 1.02-1.05) and prednisolone equivalent dose >5 mg/day (aHR, 2.39; 95% CI: 1.85-3.09) were risk factors of NAFLD in patients with RA, while prednisolone equivalent dose ≤5 mg/day (aHR of 0.53; 95% CI: 0.40-0.71) and HCQ use (aHR of 0.75; 95% CI: 0.60-0.93) were associated with a decreased risk of NAFLD. In addition, a history of hospitalizations, number of outpatient visits, age, male, and leflunomide use were associated with the development of NAFLD in some subgroups.<br />Conclusion: This study reveals that NSAID use and prednisolone equivalent dose >5 mg/day were associated with an increased risk of NAFLD in patients with RA, while the use of HCQ and prednisolone equivalent dose ≤5 mg/day decreased the risk of NAFLD.<br /> (© 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
- Subjects :
- Humans
Male
Cohort Studies
Risk Factors
Anti-Inflammatory Agents, Non-Steroidal adverse effects
Prednisolone therapeutic use
Non-alcoholic Fatty Liver Disease diagnosis
Non-alcoholic Fatty Liver Disease epidemiology
Non-alcoholic Fatty Liver Disease chemically induced
Antirheumatic Agents adverse effects
Arthritis, Rheumatoid diagnosis
Arthritis, Rheumatoid drug therapy
Arthritis, Rheumatoid epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1756-185X
- Volume :
- 27
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- International journal of rheumatic diseases
- Publication Type :
- Academic Journal
- Accession number :
- 38073585
- Full Text :
- https://doi.org/10.1111/1756-185X.15003